Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CLK1 | P49759 | 3/20 | 0.33 |
| ▸ | PDE1A | P54750 | 1/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14290282 | 0.83 | PRMT5 (0.41) | PRMT5WDR77METPOLBGGPS1 | |
| SCHEMBL4716835 | 0.76 | GGPS1 (0.58) | CYP1A2CYP2C9GGPS1FDPSMAPT | |
| SCHEMBL23108642 | 0.75 | MET (0.42) | ALDH1A1L3MBTL1PRMT5WDR77MET | |
| SCHEMBL4720762 | 0.72 | ALDH1A1 (0.42) | ALDH1A1CYP1A2CYP2C9PRMT5WDR77 | |
| SCHEMBL23132918 | 0.72 | CLK1 (0.40) | ALDH1A1PRMT5WDR77METPOLB | |
| SCHEMBL2264081 | 0.71 | PRMT5 (0.40) | PRMT5WDR77METPOLBCLK1 | |
| SCHEMBL4716274 | 0.71 | GGPS1 (0.40) | ALDH1A1L3MBTL1CYP1A2CYP2C9GGPS1 | |
| SCHEMBL4714265 | 0.69 | GGPS1 (0.37) | ALDH1A1POLBGGPS1FDPSKMT2A | |
| SCHEMBL12802351 | 0.69 | ALDH1A1 (0.55) | ALDH1A1L3MBTL1MAPTKMT2ANPC1 | |
| SCHEMBL4716769 | 0.67 | FEN1 (0.36) | GGPS1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1448561-B1 | BETA 3 ADRENERGIC AGONISTS | LILLY CO ELI (US) | 2008-02-20 | — | — | EP | disclosed |
| US-7265127-B2 | β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2007-09-04 | — | — | US | disclosed |
| US-7253181-B2 | β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2007-08-07 | — | — | US | disclosed |
| US-7241772-B2 | β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-7205407-B2 | 3-Substituted oxindole β3 agonists | ELI LILLY AND COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-7071208-B2 | β3 Adrenergic agonists | ELI LILLY AND COMPANY (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060142328-A1 | BETA 3 ADRENERGIC AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2006-06-29 | — | — | US | disclosed |
| US-20060142329-A1 | BETA 3 ADRENERGIC AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2006-06-29 | — | — | US | disclosed |
| US-20060142327-A1 | BETA 3 ADRENERGIC AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2006-06-29 | — | — | US | disclosed |
| EP-1448560-B1 | 3-SUBSTITUTED OXINDOLE beta 3 AGONISTS | LILLY CO ELI (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20050020618-A1 | Beta 3 adrenergic agonists | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2005-01-27 | — | — | US | disclosed |
| US-20050020617-A1 | 3-substituted oxindole beta3 agonists | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2005-01-27 | — | — | US | disclosed |
| EP-1448560-A1 | 3-SUBSTITUTED OXINDOLE $g(b)3 AGONISTS | ELI LILLY AND COMPANY (US) | 2004-08-25 | — | — | EP | disclosed |
| EP-1448561-A1 | BETA 3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003044017-A1 | BETA 3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2003-05-30 | — | — | WO | disclosed |
| WO-2003044016-A1 | 3-SUBSTITUTED OXINDOLE β3 AGONISTS | ELI LILLY AND COMPANY (US) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142329-A1 | BETA 3 ADRENERGIC AGONISTS | ADRB3, ADRB1, ADRB2 | ALDH1A1 354/4885L3MBTL1 3685/4885CYP1A2 492/4885 |
| US-20050020618-A1 | Beta 3 adrenergic agonists | ADRB3, ADRB1, ADRB2 | ALDH1A1 354/4885L3MBTL1 3685/4885CYP1A2 492/4885 |
| US-20050020617-A1 | 3-substituted oxindole beta3 agonists | ADRB3, ADRB2, ADRA2C | ALDH1A1 1246/4885L3MBTL1 4374/4885CYP1A2 607/4885 |
| US-20060142328-A1 | BETA 3 ADRENERGIC AGONISTS | ADRB3, ADRB1, ADRB2 | ALDH1A1 354/4885L3MBTL1 3685/4885CYP1A2 492/4885 |
| US-20060142327-A1 | BETA 3 ADRENERGIC AGONISTS | ADRB3, ADRB1, ADRB2 | ALDH1A1 226/4885L3MBTL1 3592/4885CYP1A2 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.